Page results
-
This step-by-step guide explains how you can give yourself an injection of bortezomib at home.
-
This page explains the use of botulinum toxin in the management of facial weakness and synkinesis as part of treatment process in the complex facial clinic.
-
Postnatal care should be a continuation of the care the woman has received through her pregnancy, labour and birth and take into account the woman’s individual needs and preferences.
-
To mark International Brain Tumour Awareness Week, UCLH and The National Brain Appeal are announcing a new clinical trial for patients with recurrent glioblastoma brain cancer.
-
This page explains what FACETS is and how it can help you.
-
A high quality diagnostic service for surgical neuropathology, neuromuscular diagnostics, epilepsy, molecular neuropathology of brain tumours, and neurodegenerative diseases.
-
Three patients in the UK have received an innovative treatment for the most serious form of lupus – an autoimmune condition which can cause damage to the heart, lungs, joints, brain or kidneys.
-
The UCLH Department of Rheumatology is a UK centre of excellence for clinical care, training and research.
-
Our thoracic/respiratory medicine service offers a comprehensive inpatient and outpatient medical service for adults with conditions affecting the lungs.
-
Information about the integrated women's service at the Royal London Hospital for Integrated Medicine
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology